Form 4: Nektar Therapeutics Director Robert Chess Sells Shares Under 10b5-1 Trading Plan

Robert Chess, a director at Nektar Therapeutics, sold 19,500 shares of common stock at an average price of $1.20 under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 14, 2024, Robert Chess, a director of Nektar Therapeutics, sold 19,500 shares of the company's common stock.
• The sales were executed at prices ranging from $1.19 to $1.23, with a weighted average sale price of $1.20.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
• Following the transaction, Chess directly owns 255,273 shares of Nektar Therapeutics.
• Chess also indirectly owns 2,100 shares each through his daughter and son.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a director's stock sale. The sale was conducted under a pre-arranged 10b5-1 trading plan, which reduces the likelihood of it being driven by insider information. Therefore, the sentiment is neutral.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and are closely watched by investors for signals about management's view of the company's prospects. Sales under 10b5-1 plans are generally less informative than discretionary trades, as they are pre-scheduled.

Key Dates